Search

Your search keyword '"Qi, Changsong"' showing total 220 results
Start Over Author "Qi, Changsong"
220 results on '"Qi, Changsong"'

11. 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients

Author

Qi, Changsong, primary, Guo, Rui, additional, Chen, Yan, additional, Li, Chenzhen, additional, Liu, Chang, additional, Zhang, Miao, additional, Zhang, Cheng, additional, Zhang, Xiaotian, additional, Hou, Xingguo, additional, Chen, Bo, additional, Jia, Bing, additional, Yang, Zhi, additional, Shen, Lin, additional, and Zhu, Hua, additional

Published
2024
Full Text
View/download PDF

12. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

Author

Zhang, Xiaotian, Liang, Han, Li, Ziyu, Xue, Yingwei, Wang, Yanong, Zhou, Zhiwei, Yu, Jiren, Bu, Zhaode, Chen, Lin, Du, Yian, Wang, Xinbao, Wu, Aiwen, Li, Guoli, Su, Xiangqian, Xiao, Gang, Cui, Ming, Wu, Dan, Chen, Li, Wu, Xiaojiang, Zhou, Yanbing, Zhang, Lianhai, Dang, Chengxue, He, Yulong, Zhang, Zhongtao, Sun, Yihong, Li, Yong, Chen, Huanqiu, Bai, Yuxian, Qi, Changsong, Yu, Peiwu, Zhu, Guanbao, Suo, Jian, Jia, Baoqing, Li, Leping, Huang, Changming, Li, Fei, Ye, Yingjiang, Xu, Huimian, Wang, Xin, Yuan, Yannan, E, Jian-Yu, Ying, Xiangji, Yao, Chen, Shen, Lin, and Ji, Jiafu

Published
2021
Full Text
View/download PDF

14. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Author

Xu, Yingying, Wang, Yakun, Gong, Jifang, Zhang, Xiaotian, Peng, Zhi, Sheng, Xinan, Mao, Chenyu, Fan, Qingxia, Bai, Yuxian, Ba, Yi, Jiang, Da, Yang, Fen, Qi, Changsong, Li, Jian, Wang, Xicheng, Zhou, Jun, Lu, Ming, Cao, Yanshuo, Yuan, Jiajia, Liu, Dan, Wang, Zhenghang, Fang, Jianmin, and Shen, Lin

Published
2021
Full Text
View/download PDF

16. Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

Author

Wang, Yakun, primary, Wang, Chang, additional, Chen, Xiaofeng, additional, Peng, Zhi, additional, Gu, Yanhong, additional, Wang, Yizhuo, additional, Wang, Xicheng, additional, Li, Jian, additional, Gong, Jifang, additional, Qi, Changsong, additional, Yuan, Jiajia, additional, Lu, Zhihao, additional, Lu, Ming, additional, Shen, Lin, additional, Cao, Yanshuo, additional, and Zhang, Xiaotian, additional

Published
2024
Full Text
View/download PDF

20. China special issue on gastrointestinal tumors—NTRK fusion in a large real‐world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.

Author

Qi, Changsong, Zhou, Ting, Bai, Yuezong, Chen, Hui, Yuan, Jiajia, Zhao, Feilong, Liu, Chang, Ma, Mingyang, Bei, Ting, Chen, Shiqing, Zhao, Xiaochen, Chen, Chunzhu, and Shen, Lin

Subjects
CIRCULATING tumor DNA, GENE fusion, CHINESE people, NUCLEOTIDE sequencing, GASTROINTESTINAL tumors, PROGRESSION-free survival
Abstract

Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers and targets of TRK inhibitors in solid tumors. Little is known about NTRK fusion in Chinese patients with pan‐cancer. Our study investigated the prevalence and genomic features of NTRK1/2/3 gene fusions in 67 883 Chinese patients with pan‐cancer using next‐generation sequencing (NGS) data and circulating tumor DNA (ctDNA) NGS to guide TRK inhibitor treatment and resistance monitoring. The prevalence of NTRK fusion (tissue NGS) in the pan‐cancer population was 0.18%, with 46 unique NTRK‐fusion partner pairs, of which 33 were not previously reported. NTRK2 breakpoint occurred more frequently in intron 15 than intron 12. In colorectal cancers (CRCs), compared to NTRK‐negative tumors, NTRK‐positive tumors displayed higher tumor mutational burden (TMB) levels (54.6 vs 17.7 mut/Mb, P <.0001). In microsatellite instability‐high (MSI‐H) CRC, patients with NTRK fusion had a significantly lower TMB than NTRK‐negative cases (69.3 vs 79.9 mut/Mb, P =.012). The frequency of NTRK fusion in a ctDNA NGS cohort of 20 954 patients with cancer was similar to that of the tissue NGS cohort. In eight NTRK fusion ctDNA‐positive patients, larotrectinib induced objective response in 75% of patients and median progression‐free survival was 16.3 months. Blood samples collected from a patient with disease progression after larotrectinib treatment revealed NTRK3 G623R as the potential resistance mechanism. Our study revealed previously unreported NTRK fusion partners, associations of NTRK fusion with MSI and TMB, and the potential utility of ctDNA to screen candidates for TRK inhibitors and monitor drug resistance. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

Author

Wang, Yanni, primary, Zou, Jianling, additional, Li, Yun, additional, Jiao, Xi, additional, Wang, Yujiao, additional, Zhuo, Na, additional, Gao, Mengting, additional, Gong, Jifang, additional, Li, Jian, additional, Zhang, Xiaotian, additional, Wang, Xicheng, additional, Peng, Zhi, additional, Qi, Changsong, additional, Wang, Zhenghang, additional, Li, Jie, additional, Li, Yan, additional, Shen, Lin, additional, Zhang, Henghui, additional, and Lu, Zhihao, additional

Published
2022
Full Text
View/download PDF

27. An Interpretation of Flow Graphs by Granular Computing

Author

Sun, Jigui, Liu, Huawen, Qi, Changsong, Zhang, Huijie, Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Carbonell, Jaime G., editor, Siekmann, Jörg, editor, Greco, Salvatore, editor, Hata, Yutaka, editor, Hirano, Shoji, editor, Inuiguchi, Masahiro, editor, Miyamoto, Sadaaki, editor, Nguyen, Hung Son, editor, and Słowiński, Roman, editor

Published
2006
Full Text
View/download PDF

29. A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor

Author

Zhang, Qi, primary, Deng, Ting, additional, Yang, Fen, additional, Guo, Weijian, additional, Liu, Dan, additional, Yuan, Jiajia, additional, Qi, Changsong, additional, Cao, Yanshuo, additional, Yu, Qiuqiong, additional, Cai, Huiming, additional, Peng, Zhi, additional, Wang, Xicheng, additional, Zhou, Jun, additional, Lu, Ming, additional, Gong, Jifang, additional, Li, Jian, additional, Ba, Yi, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

30. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer

Author

Wang, Yujiao, primary, Jiao, Xi, additional, Li, Shuang, additional, Chen, Huan, additional, Wei, Xin, additional, Liu, Chang, additional, Gong, Jifang, additional, Zhang, Xiaotian, additional, Wang, Xicheng, additional, Peng, Zhi, additional, Qi, Changsong, additional, Wang, Zhenghang, additional, Wang, Yanni, additional, Zhuo, Na, additional, Zou, Jianling, additional, Zhang, Henghui, additional, Li, Jian, additional, Shen, Lin, additional, and Lu, Zhihao, additional

Published
2022
Full Text
View/download PDF

32. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer

Author

Wang, Zhenghang, primary, Zhang, Qi, additional, Qi, Changsong, additional, Bai, Yuezong, additional, Zhao, Feilong, additional, Chen, Hui, additional, Li, Zhongwu, additional, Wang, Xicheng, additional, Chen, Mifen, additional, Gong, Jifang, additional, Peng, Zhi, additional, Zhang, Xiaotian, additional, Cai, Jinping, additional, Chen, Shiqing, additional, Zhao, Xiaochen, additional, Shen, Lin, additional, and Li, Jian, additional

Published
2022
Full Text
View/download PDF

33. Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.

Author

QI, Changsong, primary, Wu, Shikai, additional, Kim, In-Ho, additional, Cai, Shirong, additional, Wang, Jufeng, additional, Kim, Seung Tae, additional, Wang, Jaw-Yuan, additional, Bai, Li-Yuan, additional, Lin, Cheng-Yao, additional, Liang, Zhezhao, additional, Wei, Jian Xin, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

35. FAT4 mutation as a potential predictive biomarker for immunotherapy combined with anti-angiogenic therapy in MSS metastatic colorectal cancer.

Author

Chen, Mifen, primary, Zhang, Qi, additional, Chen, Hui, additional, Wang, Zhenghang, additional, Xu, Ting, additional, QI, Changsong, additional, Chen, Shiqing, additional, Zhao, Xiaochen, additional, Bai, Yuezong, additional, Peng, Zhi, additional, Wang, Xicheng, additional, Zhang, Xiaotian, additional, Gong, Jifang, additional, Shen, Lin, additional, and Li, Jian, additional

Published
2022
Full Text
View/download PDF

36. Genomic characterization of Chinese locally advanced or metastatic gastric cancer.

Author

Zhang, Xiaotian, primary, Wang, Yakun, additional, Xinying, Shi, additional, QI, Changsong, additional, Peng, Zhi, additional, Xie, Tong, additional, Liu, Dan, additional, Cheng, Siyuan, additional, Zhang, Panpan, additional, Zhang, Yiqun, additional, Wan, Qianhui, additional, Hu, Nana, additional, Pei, Zhihua, additional, Wang, Dongliang, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

37. Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).

Author

QI, Changsong, primary, Liu, Chang, additional, Gong, Jifang, additional, Li, Jian, additional, Liu, Dan, additional, Ge, Sai, additional, Zhang, Miao, additional, Peng, Zhi, additional, Zhou, Jun, additional, Zhang, Xiaotian, additional, Zheng, Ji, additional, Xiao, Jun, additional, Yuan, Daijing, additional, Peng, Yueying, additional, Wang, Huamao, additional, Li, Zonghai, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

38. KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-positive Advanced Gastrointestinal Cancer: a multicenter, open-label, nonrandomized, phase Ib study

Author

Dong, Zhi, primary, Gong, Jifang, additional, Liu, Dan, additional, Zhang, Xiaotian, additional, Luo, Suxia, additional, Peng, Zhi, additional, Wang, Yankun, additional, Qi, Changsong, additional, Wang, Zhenghang, additional, Li, Jian, additional, Wang, Xicheng, additional, Lu, Ming, additional, Lu, Zhihao, additional, Zhou, Jun, additional, Cao, Yansuo, additional, Yuan, Jiajia, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

40. Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II multicenter single-arm study and exploratory biomarker analysis.

Author

Xu, Ting, primary, Wang, Xicheng, additional, Xin, Ying, additional, Wang, Zhenghang, additional, Wang, Yakun, additional, Qi, Changsong, additional, Liu, Dan, additional, Li, Yanyan, additional, Gong, Jifang, additional, Li, Jian, additional, Huang, Depei, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

42. sj-docx-2-tam-10.1177_17588359221105022 – Supplemental material for Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors

Author

Xu, Ting, Wang, Xicheng, Wang, Zhenghang, Deng, Ting, Qi, Changsong, Liu, Dan, Li, Yanyan, Ji, Congcong, Li, Jian, and Shen, Lin

Subjects
110203 Respiratory Diseases, animal structures, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tam-10.1177_17588359221105022 for Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors by Ting Xu, Xicheng Wang, Zhenghang Wang, Ting Deng, Changsong Qi, Dan Liu, Yanyan Li, Congcong Ji, Jian Li and Lin Shen in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

43. sj-docx-1-tam-10.1177_17588359221105022 – Supplemental material for Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors

Author

Xu, Ting, Wang, Xicheng, Wang, Zhenghang, Deng, Ting, Qi, Changsong, Liu, Dan, Li, Yanyan, Ji, Congcong, Li, Jian, and Shen, Lin

Subjects
110203 Respiratory Diseases, animal structures, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359221105022 for Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors by Ting Xu, Xicheng Wang, Zhenghang Wang, Ting Deng, Changsong Qi, Dan Liu, Yanyan Li, Congcong Ji, Jian Li and Lin Shen in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

44. Additional file 2 of Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Author

Jia, Keren, Chen, Yang, Sun, Yu, Hu, Yajie, Jiao, Lei, Ma, Jie, Yuan, Jiajia, Qi, Changsong, Li, Yanyan, Gong, Jifang, Gao, Jing, Zhang, Xiaotian, Li, Jian, Zhang, Cheng, and Shen, Lin

Abstract

Additional file 2: Figure S1. CLDN18.2 expression in GC. Representative images of IHC-stained GC tissues with different CLDN18.2 intensity. Figure S2. The relationship between the proportion of CLDN18.2 expression and prognosis. (A) AUC curve of predicting the efficacy of anti-PD-1/PD-L1 regimens in GC based on the proportion of moderate-to-strong CLDN18.2 expression; (B) OS, irOS and irPFS of GC patients were stratified by Log-Rank test based on the proportion of moderate-to-strong CLDN18.2 expression in normal. (C) OS, irOS and irPFS of GC patients were stratified by Log-Rank test based on the balance of the proportion of moderate-to-strong CLDN18.2 expression in GC and matched normal tissues. Figure S3. The correlation of CLDN18.2 with other immune checkpoint markers in GC. "Corr" in the grey text represents the correlation coefficients in all patients. "Negative" in the green text represents the correlation coefficient in the CLDN18.2 negative group. "Positive" in the red text represents the correlation coefficient in the CLDN18.2 positive group. In histograms, dot plots, and density plots, red represents CLDN18.2-positive and green represents CLDN18.2-negativity. * P < 0.05, ** P < 0.01, and *** P < 0.001. Figure S4. The detailed immune composition according to CLDN18.2 in GC. (A) The abundance of CD8+ T cells according to CLDN18 classification in TCGA. Student t-test. * P < 0.05, ** P < 0.01, *** P < 0.001 and not significant (ns). The comparison of M1 and M2 macrophages in our cohort (B) and TCGA (C) based on CLDN18.2 classification. * P < 0.05, ** P < 0.01, *** P < 0.001 and not significant (ns). (D) An appendix heatmap presenting the rate of immune cell subtypes in TC. Figure S5. Quantitative and spatial information on immune cells in GC or adjacent normal tissues. (A) An appendix heatmap presenting the rate of immune cell subtypes in adjacent normal tissues. Effective score (B) and effective percent (C) in adjacent normal samples grouped by CLDN18.2 expression (central cells: tumor cells; peripheral cells: immune cells; radius range: 20 microns).

Published
2022
Full Text
View/download PDF

45. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

Author

Liu, Hua, Wang, Yakun, Qi, Changsong, Xie, Tong, Peng, Zhi, Li, Jian, Shen, Lin, and Zhang, Xiaotian

Subjects
Cancer Research, Oncology
Abstract

BackgroundGastric cancer (GC) is one of the most common malignant cancers worldwide. The development of potential antitumor agents is being investigated and stimulates more clinical trials. Overall survival (OS) is consistently considered the primary endpoint for clinical trials on treatment effect assessment. However, finding an appropriate endpoint more sensitive and easy for trials is vital. For adjuvant chemotherapy, current evidence has shown that disease-free survival (DFS) could be a surrogate endpoint for randomized controlled trials (RCTs) with GC, but evidence for neoadjuvant chemotherapy (NCT) or chemoradiotherapy (NCRT) is inadequate. This study was designed to evaluate the possibility that event-free survival (EFS) surrogates OS in RCTs of NCT/NCRT of gastric orss gastroesophageal (GC or GEJ) adenocarcinoma patients (ADK).MethodsA literature search was conducted through databases including PubMed, the Cochrane Library, and Embase. References and articles from other sources were also included. A total of 8 RCTs with 2,837 patients were eventually analyzed. Hazard ratios (HRs) of OS and EFS were directly approached. The surrogacy of EFS was assessed through the correlation of determination R2. We used Review Manage pooling HRs of OS and EFS at the trial level. I2 was used to demonstrate the heterogeneity of inclusions. Publication bias was summarized and illustrated through funnel plots. All analyses were on two sides with a setting statistical significance as p < 0.05.ResultsEight RCTs of 2,837 patients were analyzed at the trial level. The I2 for OS was 21% and 51% for EFS, and a fixed-effect model was used. The pooled HR of OS was 0.83 (95% CI: 0.75–0.92, p < 0.001), and that of EFS was 0.78 (95% CI: 0.71–0.86, p < 0.001). The regression correlation coefficient between EFS and OS was 0.76 (95% CI: 0.41–1.11, p = 0.002), and the coefficient of determination R2 = 0.826.ConclusionsA strong correlation was observed between OS and EFS at the trial level. EFS could be a surrogate endpoint for neoadjuvant RCTs of GC and GEJ adenocarcinoma. Further studies and evidence from individual data are expected.

Published
2021

47. A Phase Ib Study of KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-Positive Advanced Gastrointestinal Cancer

Author

Dong, Zhi, primary, Liu, Dan, additional, Gong, Jifang, additional, Zhang, Xiaotian, additional, Luo, Suxia, additional, Peng, Zhi, additional, Wang, Yakun, additional, Qi, Changsong, additional, Wang, Zhenghang, additional, Li, Jian, additional, Wang, Xicheng, additional, Lu, Ming, additional, Lu, Zhihao, additional, Zhou, Jun, additional, Cao, Yanshuo, additional, Yuan, Jiajia, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

48. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients

Author

Chen, Yang, primary, Li, Yanyan, additional, Qi, Changsong, additional, Zhang, Cheng, additional, Liu, Dan, additional, Deng, Youping, additional, Fu, Yuanyuan, additional, Khadka, Vedbar S., additional, Wang, Daisy Dandan, additional, Tan, Shanyang, additional, Liu, Shujun, additional, Peng, Zhi, additional, Gong, Jifang, additional, Lin, Peter Ping, additional, Zhang, Xiaotian, additional, Li, Jian, additional, Li, Yilin, additional, and Shen, Lin, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results